San Diego – September 15, 2016 – Cooley advised Horizon Pharma on its agreement to acquire Raptor Pharmaceutical for approximately $800 million. The transaction is expected to close in the fourth quarter.
“The proposed acquisition of Raptor furthers our commitment to helping people with rare diseases and is a significant step in advancing our strategy to expand our rare disease business,” said Timothy P Walbert, chairman, president and CEO of Horizon.
Horizon, headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases.
Cooley has a longstanding relationship with Horizon, including taking the company public in 2011. In 2015, Cooley advised Horizon on its largest acquisition to date – the acquisition of Hyperion Therapeutics for $1.1 billion, as well as its acquisition of Crealta for $510 million. Cooley helped Horizon fund this transaction through several equity and debt financings.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.
"More Rare Disease Deal Making to Follow Horizon's Raptor Deal," The Deal
"Horizon Buys Rare-Disease Company Raptor for $800 Million," The Washington Post
"Horizon Pharma Swoops in on Raptor," The Deal
"HZNP, RPTP: Horizon Pharma PLC Stock Jumps on $800 Million Raptor Pharmaceutical Corp. Buy," InvestorPlace
"Horizon Pharma Buys Rare-Disease Company Raptor for $800 Million," Crain’s Chicago Business
"Horizon Buys Rare-Disease Company Raptor for $800 Million," Bloomberg
"Horizon Pharma to Buy Raptor Pharma for $800 Mln," Reuters
"New ‘Horizon’ for Raptor in $800M Cash Deal," BioWorld